4MEDI Biotechnology Park

Project information

Index: 1210R4
Acronym:ETTBio
Priority:1: Innovation and the knowledge economy
Sub Theme:Innovation, research and technology development
Location CESKA REPUBLIKA CESKA REPUBLIKA Ostrava Moravskoslezsko Start/End date of the practice
Start: 2014

Topic of the practice

research infrastrucuture for applied research and experimental development in the field of regenerative medicine

Good Practice Information

Within Park 4MEDi, ATMP for the treatment of poorly treatable or incurable diseases will be developed, using human cells and new materials. These include treatment of ischemic diseases, diabetes, degenerative diseases, and multiple sclerosis. Park 4MEDi will be developed by Czech private investor PrimeCell together with the University Hospital Ostrava and Institute of Public Health in Ostrava.

To construct the Park, PrimeCell has received support from the Prosperity programme amounting to EUR 16 million. Its total cost stands at EUR 40 million. A total of 150 new jobs are to be created for scientists and researchers in the field of biotechnology, medicine and materials engineering. This is the largest investment in the field of Advanced Therapies in Czech Republic as well as in Europe.

Evidence of success

Despite the setup only in Sept 2014, PrimeCell company and University Hospital Ostrava are already performing several clinic trials (mostly 2nd and 3rd phase) together with foreign partners (from USA, Japan, Germany, South Korea, etc.) guaranteeing the utilisation of 4MEDI Biotechnology Park in the field of concrete applied research projects focused on regenerative medicine.

Contact details to obtain further information on the practice

David Pawera

Regional Development Agency Ostrava (RDAO)

pawera@arr.cz

www.arr.cz, www.rismsk.cz

Annex completed on: 09-17-2014

As of 31 December 2015, this website is no longer updated. Follow news on interregional cooperation at www.interregeurope.eu